Strengthening the Cost Effectiveness of Medical Countermeasure Development Against Rare Biological Threats: The Ebola Outbreak

This publication has 25 references indexed in Scilit:

• US biopharmaceutical finance and the sustainability of the biotech business model
  Research Policy, 2011
• The productivity crisis in pharmaceutical R&D
  Nature Reviews Drug Discovery, 2011
• Bio-pharma: A financialized business model
  Critical Perspectives on Accounting, 2010
• The US Orphan Drug Act: Rare disease research stimulator or commercial opportunity?
  Health Policy, 2010
• Project BioShield: What It Is, Why It Is Needed, and Its Accomplishments So Far
  Clinical Infectious Diseases, 2007
• Defence and firm financial structure in France
  Review of Financial Economics, 2007
• Pesticide risk valuation in empirical economics: a comparative approach
  Ecological Economics, 2006
• Time to disable DALYs?
  The European Journal of Health Economics, 2003
• The Financing of Research and Development
  Oxford Review of Economic Policy, 2002
• Calculating and presenting disability adjusted life years (DALYs) in cost-effectiveness analysis
  Health Policy and Planning, 2001